NCT06530251 2026-03-04
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Akeso
Phase 1/2 Recruiting
Clinical Trials
9 trialsNCT06220318 2025-11-28
Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors
Fujian Haixi Pharmaceuticals Co., Ltd.
Phase 1/2 Active not recruiting
NCT05383482 2025-11-17
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Laekna Limited
Phase 1/2 Completed
NCT06329973 2025-07-17
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer
Henan Cancer Hospital
Phase 1/2 Recruiting
NCT07025889 2025-06-18
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Ruijin Hospital
Phase 1/2 Recruiting
NCT06956716 2025-05-04
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
Zhejiang University
Phase 1/2 Recruiting
NCT03903705 2025-04-06
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors
Hutchmed
Phase 1/2 Completed
NCT06888648 2025-03-21
Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
Zhejiang University
Phase 1/2 Not yet recruiting
NCT06888674 2025-03-21
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.
Zhejiang University
Phase 1/2 Not yet recruiting